Two Drugs May Reverse Fatty Liver Disease in New Study

A combination of two existing medications has shown remarkable power to reverse fatty liver disease in a breakthrough that could help hundreds of millions worldwide.

Researchers at the University of Barcelona found that pemafibrate (a cholesterol drug) and telmisartan (a blood pressure medication) worked together to dramatically reduce liver fat in animal studies. The discovery is especially exciting because both drugs are already approved and have proven safety records.

Metabolic dysfunction-associated steatotic liver disease now affects one in three adults globally. The condition happens when excess fat builds up in liver cells, often with no symptoms until serious damage occurs. It also significantly increases the risk of dying from heart disease.

Professor Marta Alegret, who led the research, explains why existing drugs matter so much. Many experimental medications for this condition have failed clinical trials due to safety concerns. Using medications already proven safe in humans could offer a faster path to helping patients in the early stages of disease.

The team tested the drugs in both rats and zebrafish, which share important metabolic similarities with humans. The results surprised even the researchers: using half doses of both drugs together worked just as well as full doses of either drug alone.

This combination approach could mean fewer side effects while achieving the same benefits. The drugs work through different biological pathways, with telmisartan restoring a protein called PCK1 that helps the liver process nutrients differently.

The Bright Side

Beyond reversing liver fat, the treatment lowered blood pressure and cholesterol levels in the animal models. This dual action means patients could see reduced cardiovascular risk alongside improved liver health.

The research team discovered something unexpected about how telmisartan works in early-stage disease. The drug restored PCK1 protein levels, shifting the liver's metabolism away from fat storage and toward glucose production. Importantly, this didn't raise blood sugar levels, avoiding diabetes risk.

Because the condition often goes undetected until advanced stages, having a safe treatment option for early intervention could prevent millions from developing severe liver damage. Current treatment options remain extremely limited.

The findings still need human clinical trials before doctors can prescribe this combination for liver disease. However, both medications are already widely available and prescribed for other conditions, which could speed the path to patient access.

Researchers from multiple institutions collaborated on the study, including the Institute of Biomedicine and Uppsala University in Sweden. Their work represents years of effort to find safer alternatives to experimental therapies.

For the one billion people worldwide living with fatty liver disease, this research offers genuine hope that an effective treatment may already exist in pharmacy cabinets.